Showing results (41-50 of 61) with videos related to
Sort By:
Pageof 7
Journal of Hepatology|September 9, 2014
What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?Scott A McDonald, Hamish A Innes, Peter C Hayes, et al.Frontline Gastroenterology|July 27, 2018
Development and validation of diagnostic triage criteria for liver disease from a minimum data set enabling the 'intelligent LFT' pathway for the automated assessment of deranged liver enzymesMichael Hugh Miller, Andrew Fraser, Gillian Leggett, et al.Journal of Hepatology|November 21, 2017
The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimenHamish Innes, Stephen T Barclay, Peter C Hayes, et al.Alimentary Pharmacology & Therapeutics|April 15, 2020
Mortality and morbidity of locally acquired hepatitis E in the national Scottish cohort: a multicentre retrospective studySebastian J Wallace, Rachael Swann, Mhairi Donnelly, et al.The American Journal of Gastroenterology|August 16, 2022
Comparing Predicted Probability of Hepatocellular Carcinoma in Patients With Cirrhosis With the General Population: An Opportunity to Improve Risk Communication?Hamish Innes, Victoria Hamill, Scott A McDonald, et al.Methods in Molecular Biology (Clifton, N.J.)|December 2, 2011
A primer on the current state of microarray technologiesAlexander J Trachtenberg, Jae-Hyung Robert, Azza E Abdalla, et al.Alimentary Pharmacology & Therapeutics|June 4, 2019
Uptake of endoscopic screening for gastroesophageal varices and factors associated with variceal bleeding in patients with chronic hepatitis C infection and compensated cirrhosis, 2005-2016: a national database linkage studyScott A McDonald, Stephen T Barclay, Sharon J Hutchinson, et al.Journal of Viral Hepatitis|November 8, 2019
Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosisScott A McDonald, Kevin G Pollock, Stephen T Barclay, et al.BMJ Open Gastroenterology|January 7, 2022
Effect of COVID-19 on presentations of decompensated liver disease in ScotlandThomas Manship, Paul N Brennan, Iona Campbell, et al.Hepatology (Baltimore, Md.)|November 3, 2011
Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from careHamish A Innes, Sharon J Hutchinson, Samuel Allen, et al.Pageof 7